Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Pfizer Inc.
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
===Competition=== Despite Pfizer being among the leaders of the pharmaceutical industry, several other large, global drug manufacturers are in competition with Pfizer. These companies include Johnson and Johnson, Amgen, Novo Nordisk, Merck and Co, AbbVie Inc, and Eli Lilly and Co. In FY 2022, Pfizer made $31.37 billion in net income out of $100.33 billion in annual revenue. The company's market capitalization was $227 billion as of market close on 24th March 2023 [https://s28.q4cdn.com/781576035/files/doc_financials/2022/ar/PFE-2022-Form-10K-FINAL-%28without-Exhibits%29.pdf]. Market cap is used to determine a company's size and then evaluate the company's financial performance to other companies of various sizes. In investing, companies with larger market capitalizations are often safer investments as they represent more established companies with generally longer history in business carrying less risk than small-cap companies. # '''Johnson and Johnson:''' Johnson and Johnson is known for its health products, pharmaceuticals and medical devices. # '''Novo Nordisk A/S (NVO):''' Novo Nordisk is a Norweigan pharmaceutical company that focuses on treating diabetes, obesity and other serious chronic diseases and conditions. Ozempic was Novo Nordisk's top selling drug in 2022 which is an insulin therapy delivered by injection. # '''Eli Lilly and Co:''' Eli Lilly is a global drug manufacturing company which focuses on discovering, developing, manufacturing and marketing human pharmaceutical products. The company's top selling drug in FY 2022 was Trulicity which is used to treat type 2 diabetes. # '''Abbvie Inc.:''' AbbVie is a global biopharmaceutical company engaged in research and development, manufacturing, commercializing and selling innovation medicines and therapies. Its medical products span a range of healthcare-related areas such as immuology, oncology, neuroscience, etc. # '''Merck and Co. Inc:''' The company offers prescription medicines, vaccines, biologic therapies, and animal health products. Its two operating segments are pharmaceutical and animal health. Overall, Pfizer's largest competitor is Johnson and Johnson. Johnson and Johnson may not generate the same amount of revenue from its products but its market cap and total revenue make it a strong competitor. That being said, Pfizer is different from other companies because Pfizer continually emphasises innovation and its multi-billion dollar investment in R and D results in a strong and differentiated product pipeline. The organizational effectiveness of the company is constantly improving by continuously educating patients, physicians, payers and global health authorities on the benefits and risks of medicines and vaccines. Pfizer continues to evaluate, adapt and improve the organisation and business practice in order to meet customer and public needs. Pfizer establishes a "first-to-market" for biosimilar products to provide customers a lower-cost alternative immediately when available as well as providing the company with higher sales and profitability until other competitors enter the market. Pfizer's intellectual property and continuous medicine development are its competitive advantages over other companies [https://www.investopedia.com/ask/answers/052015/who-are-pfizers-pfe-main-competitors.asp].Β {| class="wikitable" |+ !Company name !Market Cap !FY 2022 Revenue !FY 2022 Net income !Top drug by revenue (FY 2022) !Revenue from top drug (FY 2022) |- |Johnson and Johnson |$423 billion |$95 billion |$17.9 billion |Darzalex |$7.9 billion [https://www.investor.jnj.com/asm/2022-annual-report] |- |Novo Nordisk A/S (NVO) |$349 billion [https://www.investopedia.com/markets/quote?tvwidgetsymbol=NVO] |$43.5 billion |$16.9 billion |Ozempic |$5.7 billion [https://www.novonordisk.com/investors/financial-results.html#results2023] |- |Eli Lilly and Co |$440 billion [https://www.investopedia.com/markets/quote?tvwidgetsymbol=LLY] |$28.5 billion |$6.2 billion |Trulicity |$5.7 billion [https://investor.lilly.com/static-files/2f9b7bb1-f955-448d-baa2-c4343d39ee62] |- |Abbvie Inc |$242 billion [https://www.investopedia.com/markets/quote?tvwidgetsymbol=ABBV] |$58.1 billion |$11.8 billion |Humira |$18.6 billion [https://investors.abbvie.com/static-files/e3047152-75b3-44b3-95a8-18e4fa991768] |- |Merck and Co. Inc |$289 billion |$59.3 billion |$16.4 billion |Keytruda |$20.9 billion [https://s21.q4cdn.com/488056881/files/doc_financials/2022/ar/b390be48-92bf-4595-96da-ac5cd7c3d92e-%281%29.pdf] |}
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)